Clinical Trial Update: An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study comparing 10 mg and 20 mg Senaparib capsules in healthy fasting Chinese subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Senaparib (senaparib)

Snippet

Sponsor: Impact Therapeutics, Inc. | Conditions: Solid Tumor | Phase 1 | Status: COMPLETED